KPV is an alpha-MSH-derived tripeptide investigated strictly for laboratory research to observe its cellular mechanisms and pathways in preclinical models. In laboratory settings, researchers investigate the KPV tripeptide to understand its specific molecular properties compared to its larger parent molecule, alpha-MSH. As an isolated synthetic compound, KPV peptide research focuses on observing intracellular behavior, cellular signaling, and targeted molecular pathways without the broader melanotropic effects associated with full-length alpha-MSH. Understanding these molecular dynamics requires strict adherence to analytical purity standards and controlled laboratory handling protocols.
Important Compliance Notice: KPV is sold exclusively for research use only (RUO) and is strictly prohibited from human consumption, medical, veterinary, or cosmetic applications. All referenced studies, mechanisms, and models reflect preclinical in vitro and in vivo laboratory investigations. This compound is not intended to diagnose, treat, cure, mitigate, or prevent any disease. No material herein constitutes human administration, dosing, or self-use protocols.
What is the KPV peptide and its mechanism of action?
KPV (Lysine-Proline-Valine) is a three-amino-acid tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that exerts anti-inflammatory effects inside cells by targeting NF-kappaB and MAPK signaling, largely via PepT1-mediated uptake in preclinical models[1][2][3][4]. Researchers investigate this compound strictly within in vitro and in vivo laboratory environments to map its distinct cellular pathways and molecular interactions.
In preclinical studies, KPV is transported across cell membranes by PepT1 (SLC15A1), a proton-coupled oligopeptide transporter expressed on specific cellular epithelia[1][2][3]. Once inside the cell, KPV accumulates in the nucleus and directly interferes with the NF-kappaB activation cascade[5][4]. Mechanistic data indicates that KPV stabilizes IkappaB-alpha and suppresses the nuclear import of p65RelA, which shortens the overall duration of NF-kappaB activation[5][4]. This interference yields a dose-dependent inhibition of NF-kappaB and subsequently decreases the transcription of NF-kappaB-dependent gene products, including IL-8, TNF-alpha, IL-1beta, and IL-6 in intestinal and immune cell models[1][2][4].
Additionally, nanomolar KPV concentrations inhibit inflammatory activation of MAPK pathways – specifically p38 and JNK – simultaneously with NF-kappaB suppression[1][2]. Current mechanistic evidence supports PepT1-mediated intracellular nuclear NF-kappaB and MAPK modulation as the primary mechanism, rather than melanocortin receptor signaling[1][2][3][4].
Laboratory investigators utilize KPV research peptides to observe these pathways in various experimental models, including DSS-induced colitis, airway epithelium studies, and wound-healing assays[6][1][3][4]. In these controlled models, oral or targeted KPV administration significantly reduced myeloperoxidase (MPO) activity and colonic expression of pro-inflammatory cytokines[1][2][7]. All such applications remain strictly restricted to laboratory investigation, as KPV is sold exclusively for research use only (RUO) and is strictly prohibited from human consumption, medical, or veterinary applications.
How does KPV compare to alpha-MSH and how is it stored?
In laboratory settings, researchers investigate the KPV tripeptide to understand its specific molecular properties compared to its larger parent molecule, alpha-MSH. While alpha-MSH is a 13-amino-acid tridecapeptide known for melanocortin receptor-mediated biology, KPV corresponds only to the C-terminal residues 11-13 of alpha-MSH[8][9]. KPV preserves much of alpha-MSH’s anti-inflammatory activity but lacks its melanocortin receptor signaling profile and pigmentation effects[8][10][9].
| Property | KPV Tripeptide | Alpha-MSH |
|---|---|---|
| Sequence Length | 3 amino acids (Lys-Pro-Val)[8][9] | 13 amino acids (tridecapeptide)[8][9] |
| Molecular Weight | 342.43 g/mol[8] | Considerably larger (full parent peptide)[8][9] |
| Core Mechanism | Receptor-independent / not MC1R-cAMP driven[11][10][12] | Melanocortin receptor-mediated (cAMP elevation)[12][13] |
| Pigmentation | Lacks alpha-MSH pigmentation effects[8] | Known for pigmentation biology[8][12] |
Preclinical studies require lyophilized KPV peptides with a verified purity threshold greater than 99 percent, confirmed through third-party HPLC and mass spectrometry testing. To maintain this rigorous purity, strict laboratory storage protocols are mandatory. Lyophilized KPV shows excellent stability in the solid state, with minimal degradation observed over 24 to 36 months when stored frozen at -20 degrees Celsius and protected from moisture and light[6]. Under these exact storage conditions, properly manufactured KPV maintains greater than 98 percent purity and full biological activity for at least two to three years[6].
For short-term laboratory handling, unopened lyophilized KPV vials may be stored at 2 to 8 degrees Celsius for up to 6 to 12 months[6]. Once a vial is opened or reconstituted for an assay, researchers must minimize moisture exposure and store the compound at -20 degrees Celsius with a desiccant[6]. Proper environmental controls – specifically avoiding temperature cycling and light exposure – are critical to preventing peptide hydrolysis and ensuring reproducible in vitro results over the course of an experiment.
Frequently Asked Questions
What is the KPV peptide?
KPV is an alpha-MSH-derived tripeptide investigated strictly for laboratory research to observe its cellular mechanisms and pathways in preclinical models. Consisting of the amino acids lysine, proline, and valine, it is a synthetic compound evaluated for its intracellular signaling behavior.
What is the mechanism of action for KPV?
In preclinical models, KPV exerts its primary mechanism of action by entering cells via the PepT1 transporter and accumulating in the nucleus[5][1][4]. Once intracellular, it directly suppresses NF-kappaB and MAPK signaling pathways, thereby reducing the expression of pro-inflammatory cytokines[1][2][4].
How does KPV compare to alpha-MSH?
KPV is the minimal C-terminal fragment (residues 11-13) of the larger 13-amino-acid alpha-MSH peptide[8][9]. While both compounds are studied for cellular suppression of inflammation, KPV achieves this via receptor-independent mechanisms and lacks the cAMP elevation and pigmentation effects associated with alpha-MSH[8][10][12].
How do you store lyophilized KPV?
Lyophilized KPV should be stored in a laboratory freezer at -20 degrees Celsius, protected from light and moisture[6]. Under these conditions, the unconstituted solid peptide maintains greater than 98 percent purity for up to 36 months[6].
References
- PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal … – PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/ (2007-10-17)
- PepT1-mediated tripeptide KPV uptake reduces intestinal … – PubMed. https://pubmed.ncbi.nlm.nih.gov/18061177/ (2008-01-27)
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid …. https://pmc.ncbi.nlm.nih.gov/articles/PMC5498804/ (2017-01-28)
- mechanism of KPV action and a role for MC3R agonists – PubMed. https://pubmed.ncbi.nlm.nih.gov/22837805/ (2026-06-19)
- Recent Advances in KPV Peptide Delivery | SciTechnol. https://www.scitechnol.com/peer-review/recent-advances-in-kpv-peptidedelivery-8OYD.php?article_id=18216 (2022-04-27)
- KPV — Molecular Specifications & Research Monograph. https://peptidebiologix.com/kpv (2026-06-02)
- KPV Peptide Therapy | Anti‑Inflammatory & Healing TX – Huemn. https://www.behuemn.com/kpv (2026-06-26)
- KPV Peptide: Anti-Inflammatory Tripeptide From Alpha-MSH. https://peptidepedia.org/longevity/kpv (2025-01-15)
- α‐MSH related peptides: a new class of anti‐inflammatory and …. https://pmc.ncbi.nlm.nih.gov/articles/PMC2095288/ (2026-03-27)
- Dissection of the anti-inflammatory effect of the core and C-terminal …. https://pubmed.ncbi.nlm.nih.gov/12750433/ (2003-08-17)
- Dissection of the Anti-Inflammatory Effect of the Core and C …. https://www.sciencedirect.com/science/article/abs/pii/S0022356524308468 (2003-08-29)
- alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV … – PubMed. https://pubmed.ncbi.nlm.nih.gov/15102092/ (2004-04-05)
- Immobilized α-melanocyte stimulating hormone 10–13 (GKPV …. https://www.sciencedirect.com/science/article/abs/pii/S0196978105004560 (2024-08-12)